Close

"Shares Are Positioned to Outperform" - Avalo Therapeutics (AVTX) PT Raised to $17 at Oppenheimer Aug 8, 2022 07:19AM
"Shares Hold Significant Upside Potential" - Oppenheimer Reiterates Outperform Rating, $5 Price Target on Avalo Therapeutics (AVTX) May 19, 2022 06:33AM
Cantor Fitzgerald Reiterates Avalo (AVTX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated Mar 2, 2022 10:56AM
Avalo Therapuetics (AVTX) is Attractive Among Small-Caps, Optimism for Both Upcoming Readouts Given Prior Proof-of-Concept - Oppenheimer Jan 7, 2022 06:37AM